View Post

Syros Announces New Preclinical Data on SY-1365 at San Antonio Breast Cancer Symposium

In Clinical Studies News by Barbara Jacoby

From: businesswire.com SY-1365 Shows Synergistic Activity in Combination with Fulvestrant in HR-Positive Breast Cancer Cells Resistant to Treatment with a CDK4/6 Inhibitor, Supporting Ongoing Clinical Investigation of the Combination Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) …

View Post

We’re on the verge of seeing cancer in a drastically different light

In In The News by Barbara Jacoby

By: Lydia Ramsey From: businessinsider.com As researchers look for new ways to approach tough-to-treat forms of cancer, many are focusing on genetics — more specifically, they’re looking at the type of genetic tweaks found in cancerous tumors. One early-stage cancer company, Loxo Oncology, hopes to eventually sequence the tumors of its patients and use that data to find out what drugs their …

View Post

​One of the coolest ideas ever to treat cancer is being developed right in Charlestown

In In The News by Barbara Jacoby

By: Don Seiffert From: bizjournals.com A year ago, Ziopharm was scarcely known in the biotech world, having recently moved from New York City to Charlestown just a couple years after one of its drugs failed a late-stage trial. Over the course of 2015, the company attracted worldwide notice for its early-stage treatments for cancer. In particular, attention has been on …